VSTM2L

Across TCGA pan-cancer cohorts, VSTM2L Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated VSTM2L data layer compared with 26 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher VSTM2L Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated VSTM2L expression acts as an unfavorable survival marker.

HNSC, LGG, and COAD are the cancer types where VSTM2L Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.069	0.768	<.001	24	view →
LGG	OS	Median	All	0.238	0.810	<.001	12	view →
COAD	OS	Median	II,III,IV	0.242	0.788	.044	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

VSTM2L–HNSC (OS)

Open the HNSC breakdown →